Treatment with arsenic has emerged as a highly successful therapy for APL (Lallemand-Breitenbach et al., 2012) as it induces degradation of both PML and the PML-RARA oncogene that cause the disease. The gene discussed is RARA; the disease is acute promyelocytic leukemia.